Form 4: Roivant Sciences Director Vivek Ramaswamy Sells Over 748,000 Shares Totaling $8.45 Million

Roivant Sciences Ltd. Director and 10% owner Vivek Ramaswamy reported the sale of 748,230 common shares across two transactions in early June 2025, totaling approximately $8.45 million.

Summary

• Vivek Ramaswamy, a Director and 10% owner of Roivant Sciences Ltd. (ROIV), reported two separate sales of common shares.
• On June 4, 2025, Ramaswamy sold 547,430 common shares at a weighted average price of $11.34 per share, with prices ranging from $11.25 to $11.47.
• On June 6, 2025, an additional 200,800 common shares were sold at a weighted average price of $11.19 per share, with prices ranging from $11.16 to $11.31.
• The total value of shares sold across both transactions amounts to approximately $8,457,898.20.
• Following these transactions, Vivek Ramaswamy directly beneficially owns 38,426,381 common shares.
• Additionally, 13,357,857 common shares are held indirectly through spousal ownership.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a key individual, even though the sales were pre-planned under a 10b5-1 program, which mitigates some of the immediate negative implications of an ad-hoc sale.

Negatives

• Significant reduction in direct beneficial ownership by a Director and 10% owner, potentially signaling reduced confidence or a diversification strategy.
• The sale of a large block of shares could exert downward pressure on the stock price.

Risks

• Investor perception risk due to a high-profile insider selling a substantial number of shares, even if pre-planned.
• Potential for increased market supply of shares if other insiders or large holders follow suit.

Future Outlook

NA

Industry Context

This Form 4 filing reports an insider transaction and does not provide broader industry context or trends. It reflects a specific individual's stock activity within the biotechnology and pharmaceutical sector.

Related Party Transactions

• The reported sales of common shares by Vivek Ramaswamy, a Director and 10% owner, constitute related party transactions.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a lack of confidence, potentially leading to negative sentiment and downward pressure on the stock price.
• The reduction in insider ownership could be viewed as a decrease in alignment between management and shareholder interests.

Key Dates

Recommendation

Keywords

Roivant Sciences, ROIV, Vivek Ramaswamy, SEC Form 4, Insider Trading, Stock Sale, Beneficial Ownership, 10b5-1 Plan